The North America Minimal Residual Disease Testing Market should witness market growth of 13.0% CAGR during the forecast period (2022-2028).
The frequently prescribed surgeries to remove a tumor, along with additional complementary therapies, do not necessarily ensure the complete eradication of malignant cells. Malignances like cancer usually leave traces in human tissues and blood.
The diagnosis of these remaining cells is essential for determining whether more chemotherapy and radiation treatments are required. This has facilitated the use of MRD tests to clear any ambiguity regarding the presence of any residues of the disease. Additionally, extensive use has led to the development of non-invasive tests to identify MRD accurately.
The detection of patient-specific MRD by utilizing T-cell receptors (TCR) or immunoglobulin (IG) is becoming more common in leukemias without a chromosomal translocation or any leukemia-specific marker. In this instance, the TCR or IG's variable region is sequenced after the leukemic-specific TCR or IG clone is generated using PCR. Such sequences help in the formation of PCR primers that will only amplify the patient's particular leukemic clone.
In the United States of America, approximately 1, 519, 907 individuals either are living with or are in remission from lymphoma, myeloma, myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDS), or leukemia. Out of this, 186, 400 were diagnosed with lymphoma, myeloma, or leukemia in 2021. According to the Leukemia & Lymphoma Society (LLS), this number accounts for 9.8% of the estimated overall cancer cases in the nation.
The US market dominated the North America Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $733.7 million by 2028.The Canada market is poised to grow at a CAGR of 15.6% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 14.5% during (2022-2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End-user, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
The frequently prescribed surgeries to remove a tumor, along with additional complementary therapies, do not necessarily ensure the complete eradication of malignant cells. Malignances like cancer usually leave traces in human tissues and blood.
The diagnosis of these remaining cells is essential for determining whether more chemotherapy and radiation treatments are required. This has facilitated the use of MRD tests to clear any ambiguity regarding the presence of any residues of the disease. Additionally, extensive use has led to the development of non-invasive tests to identify MRD accurately.
The detection of patient-specific MRD by utilizing T-cell receptors (TCR) or immunoglobulin (IG) is becoming more common in leukemias without a chromosomal translocation or any leukemia-specific marker. In this instance, the TCR or IG's variable region is sequenced after the leukemic-specific TCR or IG clone is generated using PCR. Such sequences help in the formation of PCR primers that will only amplify the patient's particular leukemic clone.
In the United States of America, approximately 1, 519, 907 individuals either are living with or are in remission from lymphoma, myeloma, myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDS), or leukemia. Out of this, 186, 400 were diagnosed with lymphoma, myeloma, or leukemia in 2021. According to the Leukemia & Lymphoma Society (LLS), this number accounts for 9.8% of the estimated overall cancer cases in the nation.
The US market dominated the North America Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $733.7 million by 2028.The Canada market is poised to grow at a CAGR of 15.6% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 14.5% during (2022-2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End-user, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
Scope of the Study
By Application
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Others
By End-user
- Hospitals & Specialty Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
By Technology
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Flow Cytometry
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F.Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Minimal Residual Disease Testing Market, by Application
1.4.2 North America Minimal Residual Disease Testing Market, by End User
1.4.3 North America Minimal Residual Disease Testing Market, by Technology
1.4.4 North America Minimal Residual Disease Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Minimal Residual Disease Testing Market by Application
3.1 North America Hematological Malignancies Market by Country
3.2 North America Leukemia Market by Country
3.3 North America Lymphoma Market by Country
3.4 North America Solid Tumors Market by Country
3.5 North America Others Market by Country
Chapter 4. North America Minimal Residual Disease Testing Market by End User
4.1 North America Hospitals & Specialty Clinics Market by Country
4.2 North America Diagnostic Laboratories Market by Country
4.3 North America Academic & Research Institutes Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Minimal Residual Disease Testing Market by Technology
5.1 North America Polymerase Chain Reaction (PCR) Market by Country
5.2 North America Next-Generation Sequencing (NGS) Market by Country
5.3 North America Flow Cytometry Market by Country
5.4 North America Others Market by Country
Chapter 6. North America Minimal Residual Disease Testing Market by Country
6.1 US Minimal Residual Disease Testing Market
6.1.1 US Minimal Residual Disease Testing Market by Application
6.1.2 US Minimal Residual Disease Testing Market by End User
6.1.3 US Minimal Residual Disease Testing Market by Technology
6.2 Canada Minimal Residual Disease Testing Market
6.2.1 Canada Minimal Residual Disease Testing Market by Application
6.2.2 Canada Minimal Residual Disease Testing Market by End User
6.2.3 Canada Minimal Residual Disease Testing Market by Technology
6.3 Mexico Minimal Residual Disease Testing Market
6.3.1 Mexico Minimal Residual Disease Testing Market by Application
6.3.2 Mexico Minimal Residual Disease Testing Market by End User
6.3.3 Mexico Minimal Residual Disease Testing Market by Technology
6.4 Rest of North America Minimal Residual Disease Testing Market
6.4.1 Rest of North America Minimal Residual Disease Testing Market by Application
6.4.2 Rest of North America Minimal Residual Disease Testing Market by End User
6.4.3 Rest of North America Minimal Residual Disease Testing Market by Technology
Chapter 7. Company Profiles
7.1 Bio-Rad Laboratories, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Guardant Health, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Invitae Corporation (ArcherDX, Inc.)
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 Bio-Techne Corporation
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trails:
7.6 ICON plc (MolecularMD Corporation)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Natera Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Sysmex Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Laboratory Corporation of America Holdings
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Product Launches and Product Expansions:
7.10. Invivoscribe, Inc.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F. Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Methodology
LOADING...
